Drug Profile
Research programme: intranasal human papillomavirus vaccine - DelSite/NCI
Latest Information Update: 22 Oct 2009
Price :
$50
*
At a glance
- Originator DelSite Biotechnologies; National Cancer Institute (USA)
- Developer National Cancer Institute (USA)
- Class Virus-like particle vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Human papillomavirus infections
Most Recent Events
- 22 Oct 2009 Discontinued - Preclinical for Human papillomavirus infections in USA (Intranasal)
- 02 Oct 2006 Preclinical trials in Human papillomavirus infections in USA (Intranasal)